Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 19, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

ACCESSWIRE IA September 19, 2019

DEADLINE: Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS

ACCESSWIRE IA September 19, 2019

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contact the Firm

GlobeNewswire September 18, 2019

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 18, 2019

GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC

ACCESSWIRE IA September 18, 2019

SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS

GlobeNewswire September 17, 2019

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 17, 2019

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 16, 2019

Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

GlobeNewswire September 16, 2019

GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC

ACCESSWIRE IA September 16, 2019

ACRS NOTICE, ROSEN, A LEADING FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS

ACCESSWIRE IA September 16, 2019

UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

GlobeNewswire September 16, 2019

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm

GlobeNewswire September 16, 2019

SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 14, 2019

Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS

ACCESSWIRE IA September 13, 2019

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 13, 2019

SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019

ACCESSWIRE IA September 13, 2019

IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA September 12, 2019

GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS

Business Wire September 12, 2019